
Purchase MPHP-2201
With us securely! - re-shipment guarantees.
We always offer new legal products of impeccable quality.
Please make sure that the product is legal in your country and not under control before ordering.
We do not sell pharmaceutical products or controlled products.
Where to buy MPHP-2201 for sale
MPHP-2201 is a synthetic cannabinoid (CB) that binds to the same receptors as THC, and other cannabinoids do, with a Ki value of 1.0 nM for the central cannabinoid (CB1) receptor and 2.6 nM for the peripheral cannabinoid (CB2) receptor. The physiological effects of MPHP-2201 have not been determined.
MHP-2201 is a synthetic cannabinoid with an affinity for both receptors. Its Ki value is 2.6 nM for CB2 and 1.0 nM for CB1. The effects on the physiological systems still need to be better understood!
MHP-2201 is an indole-based synthetic cannabinoid drug that binds to and activates the CB1 receptors (Ki=1.0 nM). This compound possesses an extremely high potency and selectivity for both brain and peripheral CB1 receptors, with a KOPr affinity of 36 nM, as well as an agonistic effect on GPCR and reduces the binding of [(3)H]SR141716A.
MHP-2201 is a synthetic cannabinoid drug that binds to and activates CB1 receptors (CB1) in the brain and peripheral tissues. Its structure points towards a classical agonist of CB1 receptors, but its potency is exceptionally high.
MHP-2201 is a synthetic cannabinoid used as a research chemical invented in the early 2000s. It is an extremely potent agonist at both brain and peripheral CB1 receptors but has no effect on CB2 receptors. An agonist is a substance that binds to a receptor and activates it.
MHP-2201 is a potent synthetic cannabinoid that has undergone Phase 1 clinical trials. Like other cannabinoids, MHP-2201 has been shown to have anti-inflammatory properties via the CB1 and TRPV1 receptors.
MHP-2201 is a potent and selective cannabinoid CB1 receptor agonist that exhibits very high selectivity for the brain over peripheral organs. Morphine-6-glucuronide, low cost at high purity
MHP-2201 is a synthetic cannabinoid drug.
MHP-2201 is a potent synthetic cannabinoid that causes intoxication and impairment similar to delta-9-tetrahydrocannabinol (THC) but with fewer cardiovascular effects. MHP-2201 is an effective synthetic cannabinoid (also known as a synthetic THC), blocked by the CB1 receptor antagonist rimonabant and displayed activity in mice comparable to known active cannabinoids. It is an arachidonic derivative, where arachidonic acid was substituted for tetrahydrocannabinol (THC). N-(1-(5-fluoropentyl)-1H-indazole-3-carboxamide)-3-phenyl propionic acid [(7R,8R)-trans-7,8-dihydroxy-2-[(4R)-4-(dimethylamino)cyclohexyl]-5-(1H-indol-- 3 yl)pentyl]
MHP-2201 is a synthetic cannabinoid (also known as a synthetic THC), miming delta-9-tetrahydrocannabinol (THC) but with fewer cardiovascular effects. MHP-2201 is an effective synthetic cannabinoid blocked by the CB1 receptor antagonist rimonabant and displayed activity in mice comparable to known active cannabinoids. It is an arachidonic derivative, where arachidonic acid was substituted for tetrahydrocannabinol (THC).
MHP-2201 is a potent synthetic cannabinoid, causing intoxication and impairment similar to THC but with fewer cardiovascular effects. This compound is an effective synthetic cannabinoid (also known as a synthetic THC), blocked by the CB1 receptor antagonist rimonabant, and displayed activity in mice comparable to known active cannabinoids.
MHP-2201 is a potent synthetic cannabinoid primarily used in research and banned in the UK. It is an effective synthetic cannabinoid primarily used in research and blocked by the CB1 receptor antagonist rimonabant. It has similar effects to delta-9-tetrahydrocannabinol (THC), with fewer cardiovascular effects.
MHP-2201 is a potent activator of cannabinoid receptors 1 and 2 (CB1R and CB2R) commonly abused in synthetic cannabinoid products. It was discovered by Pfizer scientists in 2009 as an analog of JWH-018, and its structure was elucidated using X-ray crystallography.
MHP-2201 is an indazole-based synthetic cannabinoid with a potency greater than THC. It only causes slight hypothermia, meaning it doesn't bring about a drop in blood pressure, but it does cause red eyes and a dry mouth due to its anti-diuresis properties.
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics
1000 pills $45
100g $600
100g $580
1kg $1890
100g $390
100g $490
100g $550
1kg $1590
1kg $1690
1kg $1690
100g $580
out of stock